Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Completes Acquisition of CRI

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today said that it has completed the acquisition of privately held Cambridge Research & Instrumentation for approximately $20 million.

Caliper announced the deal to acquire the Woburn, Mass.-based firm two weeks ago. The acquisition expands Caliper's life sciences tools portfolio in clinical research, pathology, and clinical market applications.

Caliper paid approximately $7.9 million in cash, $10.3 million in stock, and assumed around $1.8 million of debt. The common stock portion included issuing around 1.6 million shares of its common stock.

"CRi's products provide an entry point for Caliper to address the expanding billion-dollar tissue imaging and digital pathology clinical research market," Caliper President and CEO Kevin Hrusovsky said in a statement. "In addition, CRi's technologies enhance our toolkit of proprietary technologies for creating new product solutions to advance our vision to transform 'sick care' to 'health care' through next-generation biomarker discovery, patient stratification studies, and companion diagnostics for personalized medicine."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.